Publications

  1. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart K, Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76. 2314135
    View PubMed
  2. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013 Feb; 54(2):387-96. Epub 2012 Aug 27. 2300492
    View PubMed
  3. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4; 120(14):2817-25. Epub 2012 Jul 25. 2281319
    View PubMed
  4. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foa R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients >/=65 years old with relapsed or refractory multiple myeloma. Int J Hematol. 2012 Aug; 96(2):254-62. Epub 2012 Jul 03. 2297380
    View PubMed
  5. Kasyapa CS, Sher T, Chanan-Khan AA. Multiple myeloma and immunomodulation: regulating the regulatory cells. Leuk Lymphoma. 2012 Jul; 53(7):1253-4. Epub 2012 Apr 03. 2233886
    View PubMed
  6. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012 Jul-Aug; 10(4):155-9. Epub 2012 Jan 04. 2257601
    View PubMed
  7. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012 Jul; 158(1):91-8. Epub 2012 Apr 26. 2254408
    View PubMed
  8. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012 Apr 15; 18(8):2145-63. Epub 2012 Feb 10. 2224204
    View PubMed
  9. Smonskey MT, Block AW, Deeb G, Chanan-Khan AA, Bernstein ZP, Miller KC, Wallace PK, Starostik P. Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detection. Am J Clin Pathol. 2012 Apr; 137(4):641-6. 2233883
    View PubMed
  10. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr; 157(1):59-66. Epub 2011 Dec 15. 2211844
    View PubMed
  11. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011 Nov; 155(4):457-67. Epub 2011 Oct 20. 2209021
    View PubMed
  12. Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, Shaughnessy JP Jr, Boise LH, Chanan-Khan A, Lee KP. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol. 2011 Aug 1; 187(3):1243-53. Epub 2011 Jun 29. 2183109
    View PubMed
  13. Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul; 154(1):104-10. Epub 2011 May 09. 2212388
    View PubMed
  14. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011 Jun; 7(6):765-74. Epub 2011 Apr 27. 2212386
    View PubMed
  15. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 5; 117(18):4701-5. Epub 2011 Feb 03. 2188498
    View PubMed
  16. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79. Epub 2011 Jan 10. 2252996
    View PubMed
  17. Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K, Lee K, Chanan-Khan AA. Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. J Clin Oncol. 2011 Jan 20; 29(3):e47-9. Epub 2010 Oct 18. 2252994
    View PubMed
  18. Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A. Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther. 2011; 4:169-83. Epub 2011 Nov 04. 2235909
    View PubMed
  19. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84. Epub 2010 Oct 18. 2206663
    View PubMed
  20. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG, International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010 Oct; 24(10):1700-12. Epub 2010 Sep 02. 2206644
    View PubMed
  21. Miller KC, Musial L, Whitworth A, Chanan-Khan A. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin J Oncol Nurs. 2010 Aug; 14(4):491-9. 2194524
    View PubMed
  22. Chanan-Khan A, Kipps T, Stilgenbauer S. Clinical Roundtable Monography. events Clin Adv Hematol Oncol 8(8)suppl 1-15. 2010 Aug; New alternatives in CLL Therapy:Managing Adverse. 2252995
  23. Ailawadhi S, Masood A, Sher T, Miller KC, L H, Wood M, Lee K, Chanan-Khan A. Treatment Options for Multiple Myeloma Patients with High-Risk Disease Medical Oncology. 2010 Apr 14. [Epub ahead of print] 2194515
  24. Chanan-Khan A, Giralt S. The importance of achieving a complete response in multiple myeloma, and the impact of novel agens. J Clin Oncol. 2010 Apr 12. [Epub ahead of print] 2194507
  25. Sher T, Miller K, Deeb G, Lee K, Chanan-Khan A. Plasma Cell Leukemia and Other Aggressive Plasma Cell Malignancies. British J Haematol. 2010 Apr 6. [Epub ahead of print] 2194516
  26. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein M, Miller K, Wood M, Sher T, Liu H, Lee K, Chanan-Khan, A. Single Agent Lenalidomide in Newly Diagnosed Multiple Myeloma: A retrospective analysis. Leuk Lymphoma. 2010 April 6. 2194518
  27. Ciesielski M, Ahluwalia M, Munich S, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor Cytotoxic T Cell Response Induced by a Survivin Peptide Mimic. Cancer Immunol Immunother. 2010; 59(8). 2194521
  28. Chanan-Khan A, Borrello I, Lee K, Reece D. Development of Target-Specific Treatments in Multiple Myeloma. British Journal of Haematology. 2010. 2194522
  29. Chanan-Khan A, Musial L, Miller KC, Lawrence D, Whitworth A, Padmanabhan S, Wilding GE, Ailawadhi S, Patel M, Sher T, Bangia N, Zeldis JB, Bilgrami S, Czuczman MS, Wallace PK, Desai S, Lee K. Lenalidomide-Associated Tumor Flare Reaction in Patients with Chronic Lymphocytic Leukemia. Cancer. 2010. 2194525
  30. Ailawadhi S, Abdelhalim AN, Derby L, Miller KC, Mashtare TL, Wilding GE, Gottlieb R, Alberico RA, Klippenstein DL, Mohr A, Padmanabhan S, Lee K, Chanan-Khan AA. Extent of disease burden determined by magnetic resonance imaging of the bone marrow (BM-MRI) is predictive of survival outcome in patients with multiple myeloma. Cancer. 2010; 116(17):84. 2194510
  31. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated with surviving and p53 status but not cancer cell types. J Exp Clin Cancer Res 8. 2010; 29(1). 2194511
  32. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman M, Miller A, Lawrence W, Bilgrami S, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. LeukLymphoma. 2010; 51(1):85-8. 2194512
  33. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42. 2194506
  34. Patel MP, Chanan-Khan AA. The many lives of thalidomide. Leuk Lymphoma. 2009; 50(6):861-2. 2194500
  35. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jaganath S. Phase III randomized study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma. 2009; 50(4):559-65. 2194501
  36. Sher T, Miller K, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma. 2009; 9(4):328-30. 2194502
  37. Richardson PG, Xie W, Mitsiades CS, Chanan-Khan A, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter D, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi N, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato A. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27(21):3518-25. 2194503
  38. Patel MP, Masood A, Patel PS, Chanan-Khan AA. Targeting the Bcl-2. Curr Opin Oncol. 2009; 21:516-523. 2194504
  39. O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan A, Seymour JF, Gribben J, Itri LM, Rai KR. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized phase 3 trial of fludarabine plus cyclophosphamide with our without oblimersen: the Oblimersen CLL Study Group. J Clin Oncol. 2009; 27(31):5208-12. 2194505
  40. Ghoshal P, Nganga A, Moran-Giuati J, Szafranek A, Johnson T, Bigelow A, Houde C, avet- Loiseau H, Smiraglia D, Chanan-Khan A, Coignet L. Loss of the SMRT/NCoR2 co-repressor correlates with JAG2 over-expression in multiple myeloma. Cancer Res. 2009; 69(10):4380-7. 2194438
  41. Chanan-Khan A, Miller K, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein Z, Barcos M, Patel M, Iancu D, Lee K, Czuczman M. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma. 2009; 50(7):1096-101. 2194439
  42. Chanan-Khan AA, Sonneveld P, Harousseau JL, Richardson PG. Reply to C.A. Dasanu et al. J Clin Oncol. 2008 Oct 10; 26(29):4784-90. 2194437
  43. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Onc. 2008; 26(9):1544-52. 2194426
  44. Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008; 26(9):4851-2. 2194430
  45. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26:4784-90. 2194432
  46. Rodgers GM 3rd, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vig R: National C Cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008; 6:536-64. 2194435
  47. Moysich KB, Bonner MR, Beehler GP, Marshall JR, Menezes RJ, Baker JA, Weiss JR, Chanan-Khan A. Regular analgesic use and risk of multiple myeloma. Leuk Res. 2007; 31(4):547-51. 2194410
  48. Chanan-Khan A, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007; 109(6):2604-6. 2194412
  49. Manochakian R, Miller KC, Chanan-Khan A. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Clin Lymphoma Myeloma. 2007; 7(4):266-71. 2194413
  50. O'Brien S, Moore JO, Boyd TE, Larratt, LM, Skotnicki, A, Koziner, B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR, et al. Randomized Phase 3 Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 Antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2007; 25(9):1114-20. 2194416
  51. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yaholom J, Yunus F, National Compreh Multiple Myeloma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007; 5(3):118-147. 2194417
  52. Chanan-Khan A, Lee K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clin Lymphoma. 2007; 48(6):1228-30. 2194418
  53. Reddy N, Karampelas I, Chanan-Khan A, Fenstermaker R, Padmanabhan S. Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leu Lymph. 2007; 48(6):1228-30. 2194419
  54. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo D, Bennett MK, van Leeuwen, FW, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood. 2007; 110(9):3281-90. 2194420
  55. Manochakian R, Miller KC, Chanan-Khan A. Clinical impact of bortezomib in front-line regimens for patients with multiple myeloma. Oncology. 2007; 12(8):978-90. 2194421
  56. Chanan-Khan. New treatments for chronic lymphocytic leukemia. Curr Oncol Rep 9 (5) 353-360. 2007; 9(5):353-360. 2194422
  57. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Patin J, Yu Z, Olesnyckyj M, Zeldis J, Knight R. Randomized, Phase III, Placebo-Controlled Trial of Lenalidomide in Combination With High- Dose Dexamethasone for Relapsed or Primary Refractory Multiple Myeloma. N Engl J Med. 2007; 357(21):2133-42. 2194424
  58. O’Connor OA, Smith EA, Toner LE, Teruyda-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A. The combination of the proteasome inhibitor Bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res. 2006; 12(9):2902-11. 2194404
  59. Chanan-Khan A, Porter C. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006; 7:480-8. 2194408
  60. Chanan-Khan A, Miller KC. Supportive care in multiple myeloma. Clin Lymphoma Myeloma. 2006; 7(1):42-50. 2194409
  61. Miller KC, Padmanabhan S, DiMicelli L, DePaolo D, Landrigan B, Yu J, Doran, Marshal P, Chanan-Khan A. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma. 2006; 47(11):2339-43. 2194415
  62. Chanan-Khan A, Miller, KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 24(34):5343-9. 2194411
  63. Chanan-Khan A. Bcl-2 Antisense Therapy in B-cell Malignancies. Blood Reviews. 2005; 19(4):213-21. 2194385
  64. Czuczman MS, Fallon A, Stewart C, Donohue K, Blumerson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri FJ, Skippe M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005; 23(4):694-704. 2194388
  65. Scarpace S, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, van Besien K, McCarthy Jr P. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005; 46(2):239-42. 2194397
  66. Chanan-Khan A, Holkova B, Goldenberg AS, Pavlic A, Demopoulos R, Takeshita K. Non-Hodgkin’s lymphoma presenting as a breast mass in patients with HIV infection: A Report of three cases. Leuk Lymphoma. 2005; 46(8):1189-93. 2194399
  67. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Results of a phase I clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment - requiring chronic lymphocytic leukemia (CLL). Blood. 2005; 106:3348-52. 2194401
  68. Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Cancer- and treatment-related anemia. J Nat Compr Canc Netw. 2005; 3(6):773-89. 2194402
  69. Ramanarayanan J, Hernandez-Ilizaliturri F, Chanan-Khan A, Czuczman M. Pro-apoptotic therapy with the oligonucleotide Genasense(tm) (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumor activity of rituximab. British Journal ofHematology. 2004; 127(5):519-530. 2194391
  70. Chanan-Khan A. Bcl-2 Antisense Therapy in Hematologic Malignancies. Current Opinion in Oncology. 2004; 16(6):581-5. 2194393
  71. Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P. Long-term survival with allogeneic stem cell transplant following salvage therapy with anti-CD 52 monoclonal antibody (Campath®) in a patient with α/β hepatosplenic Tcell non-Hodgkin’s lymphoma. Leukemia & Lymphoma. 2004; 45(8):1673-5. 2194378
  72. Chanan-Khan A, Sirinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. Journal of Supportive Oncology. 2004; 2(3):251-6. 2194379
  73. Srinivasan S, Takeshita K, Holkova B, Czuczman MS, Bernstein ZP, Miller K, Driscoll D, Chanan-Khan A. Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of highly active antiretroviral therapy (HAART). HIV Clinical Trials. 2004; 5(3):140-5. 2194381
  74. Chanan-Khan A, Czuczman MS. Bcl-2 Antisense Therapy in B-cell Malignant Proliferative Disorders. Current Treatment Options in Oncology. 2004; 5(4):261-7. 2194382
  75. Chanan-Khan A. Bcl-2 Antisense Therapy in the Treatment of Multiple Myeloma. Oncology. 2004; 18(13 suppl 10):21-4. 2194384
  76. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan AA, Czuczman MS, Slack J, Wetzler M, Mookerjee BK, Silva J, McCarthy PL Jr. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003 Aug; 32(4):405-10. 1732618
    View PubMed
  77. Chanan-Khan A, Holkova B, Perle MA, Reich E, Wu CD, Takeshita K. T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica. 2003; 88(05):ECR14. 2194370
  78. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan AA, Becker JL, McCarthy PL. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin’s lymphoma patients. Bone Marrow Transplant. 2003; 32(2):139-43. 2194372
  79. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Annals of Oncology. 2003; 14(9):1430-7. 2194374
  80. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61. 1317478
    View PubMed
  81. Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker J, McCarthy P, Alam A. Thalidomide as salvage therapy for VAD-refractory multiple myeloma patients prior to autologous PBSCT. Bone Marrow Transplant. 2002; 29:577-80. 2194354
  82. Bernstein ZP, Brooks SP, Chanan-Khan A, Gollnick SO, Gilbert MJ, Tomasi TB. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Restores Allostimulatory Function to Accessory Cells in Patients with AIDS. HIV Clinical Trials. 2002; 3(3):219-24. 2194356
  83. Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, Metselaar JM, Storm G, Chanan-Khan A, Liebes L, Muggia FM, Cohen R, Barenholz Y, Alving, CR. Role of complement activation in hypersensitivity reactions to Doxil and Hynic PEG Liposomes: Experimental and clinical studies J of Liposome Research. 2002; 12:165-72. 2194361
  84. Chanan-Khan A, Czuczman MS. Radioimmunotherapy in non-Hodgkin’s lymphoma. Curr Opin Oncol. 2002; 14:484-9. 2194364
  85. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A. Effect of highly active antiretroviral therapy on survival in patients with AIDSassociated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol. 2001; 19(18):3848-51. 2194349